Electrosteel Castings (500128) Q1 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 26/27 earnings summary
25 Oct, 2026Executive summary
Q1 FY27 consolidated revenue and PAT declined YoY; EBITDA and PAT improved QoQ as cost optimization, inventory control and efficiency actions supported profitability amid weak demand.
H2FY27 recovery is expected as water-infrastructure funding and project execution improve; diversification into valves, industrial coatings and adjacent businesses aims to broaden growth.
Financial highlights
Consolidated revenue from operations was ₹142,556.96 lakh versus ₹153,021.17 lakh YoY; total income was ₹146,481.19 lakh versus ₹155,769.29 lakh.
Consolidated EBITDA was ₹139 crore, down 29.8% YoY, at a 9.5% margin; PAT was ₹4,836.67 lakh versus ₹8,907.83 lakh.
Standalone revenue from operations was ₹1,091 crore, down 22.2% YoY; EBITDA was ₹71 crore and PAT ₹6 crore, with a 6.3% EBITDA margin.
DI and CI pipe and fittings volume was 1.20 lakh tonnes, down 27% YoY; consolidated net debt was ₹876 crore at June 30, 2026.
Consolidated diluted EPS was ₹0.78 versus ₹1.44 in Q1FY26; Q1FY27 had no exceptional item, versus a ₹38 crore exceptional loss in Q1FY26.
Outlook and guidance
FY27 DI and CI pipe volume expectation was reduced from 650,000–700,000 tonnes to ~575,000 tonnes; H1 is expected to be slower, with recovery in H2.
Q2 EBITDA margin is expected to be at least in line with Q1; Q3 and Q4 margins are expected to reach 12%–13%.
Exports are targeted at 22%–25% of FY27 volumes; 60%–70% of exports are aimed at Western markets, with the balance across the Middle East, Africa and Southeast Asia.
FY30–FY31 targets include ₹7,000–8,000 crore revenue and a 13.5% EBITDA margin, assuming DI pipe demand normalizes; valve revenue is targeted to double in four years.
Latest events from Electrosteel Castings
- EBITDA doubled as DI pipe demand lifted Q1 results; legal exposures remain unresolved.500128
Q1 24/25 - H1 growth and FY26 expansion plans contrasted with weaker Q2 and qualified review.500128
Q2 24/25 - Shutdown-hit Q3 contrasted with nine-month growth and capacity expansion amid unresolved audit matters.500128
Q3 24/25 - Shutdown-hit FY25 earnings, capacity expansion and unresolved audit matters define the outlook.500128
Q4 24/25 - Funding slowdown cut Q1 earnings; H2 recovery and T.I.S. valve expansion shape the outlook.500128
Q1 25/26 - Weak JJM funding cut Q2 earnings; demand and volumes are expected to recover.500128
Q2 25/26 - JJM delays weakened Q3 earnings; exports and funding resumption underpin recovery hopes.500128
Q3 25/26 - FY26 earnings fell on weak domestic demand; gradual recovery faces cost and audit risks.500128
Q4 25/26